Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 23, 2022
To use stroke 911 to improve stroke awareness for countries where 911 is used as an emergency phone number.
Journal: CNS neuroscience & therapeutics
Published: May 04, 2022
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: July 25, 2020
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: March 20, 2020
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: October 04, 2019
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Journal: Leukemia & lymphoma
Published: September 25, 2019
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: August 12, 2019
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Journal: Clinical pharmacokinetics
Published: June 19, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026